Meeting Coverage

CROI 2017 Investigational 2-Drug HIV Regimen Showing Promise

Investigational 2-Drug HIV Regimen Showing Promise

Investigational combination of a once-daily 2-drug regimen of dolutegravir plus rilpivirine may be as effective as a 3- or 4-drug current antiretroviral regimen in HIV-1-infected patients.

CROI 2017 Multiple Viral Load Value Testing May Better Inform HIV Transmission Potential

Multiple Viral Load Value Testing May Better Inform HIV Transmission Potential

Viral loads can fluctuate over time depending on patients' access and response to HIV treatment, their medication adherence behavior, and care status.

CROI 2017 Potential New Drug Option for Treatment-Naïve HIV-1 Patients

Potential New Drug Option for Treatment-Naïve HIV-1 Patients

The once-daily dosing doravirine appears to have similar efficacy and to be non-inferior to once-daily ritonavir-boosted darunavir (DRV+r) on a background of 2 NRTIs in HIV-1 treatment-naïve adults.

CROI 2017 Study Supports Current Prevention Interventions for Zika Exposure

Study Supports Current Prevention Interventions for Zika Exposure

The current sexual prevention guidelines recommend that men use condoms or abstain from sex for 6 months after Zika virus exposure. Now there are strong data to support these guidelines.

CROI 2017 Advances in the Battle Against HIV/AIDS to be Highlighted at CROI 2017

Advances in the Battle Against HIV/AIDS to be Highlighted at CROI 2017

Vaccines against HIV/AIDS enter a new era.

Upcoming Meetings

Sign Up for Free e-newsletters